Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

The transcription factor c-Myb regulates CD8+ T cell stemness and antitumor immunity.

Gautam S, Fioravanti J, Zhu W, Le Gall JB, Brohawn P, Lacey NE, Hu J, Hocker JD, Hawk NV, Kapoor V, Telford WG, Gurusamy D, Yu Z, Bhandoola A, Xue HH, Roychoudhuri R, Higgs BW, Restifo NP, Bender TP, Ji Y, Gattinoni L.

Nat Immunol. 2019 Mar;20(3):337-349. doi: 10.1038/s41590-018-0311-z. Epub 2019 Feb 18.

2.

Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab.

Raja R, Kuziora M, Brohawn PZ, Higgs BW, Gupta A, Dennis PA, Ranade K.

Clin Cancer Res. 2018 Dec 15;24(24):6212-6222. doi: 10.1158/1078-0432.CCR-18-0386. Epub 2018 Aug 9.

PMID:
30093454
3.

Baseline Plasma Cell Gene Signature Predicts Improvement in Systemic Sclerosis Skin Scores Following Treatment With Inebilizumab (MEDI-551) and Correlates With Disease Activity in Systemic Lupus Erythematosus and Chronic Obstructive Pulmonary Disease.

Streicher K, Sridhar S, Kuziora M, Morehouse CA, Higgs BW, Sebastian Y, Groves CJ, Pilataxi F, Brohawn PZ, Herbst R, Ranade K.

Arthritis Rheumatol. 2018 Dec;70(12):2087-2095. doi: 10.1002/art.40656. Epub 2018 Oct 22.

PMID:
29956883
4.

Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab.

Higgs BW, Morehouse CA, Streicher K, Brohawn PZ, Pilataxi F, Gupta A, Ranade K.

Clin Cancer Res. 2018 Aug 15;24(16):3857-3866. doi: 10.1158/1078-0432.CCR-17-3451. Epub 2018 May 1.

5.

Distinct and common expression of receptors for inflammatory mediators in vagal nodose versus jugular capsaicin-sensitive/TRPV1-positive neurons detected by low input RNA sequencing.

Wang J, Kollarik M, Ru F, Sun H, McNeil B, Dong X, Stephens G, Korolevich S, Brohawn P, Kolbeck R, Undem B.

PLoS One. 2017 Oct 5;12(10):e0185985. doi: 10.1371/journal.pone.0185985. eCollection 2017.

6.

Generation of a functional humanized Delta-like ligand 4 transgenic mouse model.

Wiseman J, Gregersson P, Johansson J, Magnell K, Pilataxi F, Morehouse C, Brohawn P, Holoweckyj N, Strout P, Cho S.

Transgenic Res. 2017 Dec;26(6):791-798. doi: 10.1007/s11248-017-0040-3. Epub 2017 Aug 17.

PMID:
28819706
7.

Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.

Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, Illei GG, Drappa J, Wang L, Yoo S; CD1013 Study Investigators.

Arthritis Rheumatol. 2017 Feb;69(2):376-386. doi: 10.1002/art.39962.

8.

Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus.

Greth W, Robbie GJ, Brohawn P, Hultquist M, Yao B.

Immunotherapy. 2017 Jan;9(1):57-70. doi: 10.2217/imt-2016-0090. Review.

PMID:
28000522
9.

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery.

Mosely SI, Prime JE, Sainson RC, Koopmann JO, Wang DY, Greenawalt DM, Ahdesmaki MJ, Leyland R, Mullins S, Pacelli L, Marcus D, Anderton J, Watkins A, Coates Ulrichsen J, Brohawn P, Higgs BW, McCourt M, Jones H, Harper JA, Morrow M, Valge-Archer V, Stewart R, Dovedi SJ, Wilkinson RW.

Cancer Immunol Res. 2017 Jan;5(1):29-41. doi: 10.1158/2326-6066.CIR-16-0114. Epub 2016 Dec 6.

10.

Autoimmune manifestations in aged mice arise from early-life immune dysregulation.

Mahmoud TI, Wang J, Karnell JL, Wang Q, Wang S, Naiman B, Gross P, Brohawn PZ, Morehouse C, Aoyama J, Wasserfall C, Carter L, Atkinson MA, Serreze DV, Braley-Mullen H, Mustelin T, Kolbeck R, Herbst R, Ettinger R.

Sci Transl Med. 2016 Oct 19;8(361):361ra137.

11.

Type I IFNs Regulate Inflammation, Vasculopathy, and Fibrosis in Chronic Cutaneous Graft-versus-Host Disease.

Delaney TA, Morehouse C, Brohawn PZ, Groves C, Colonna M, Yao Y, Sanjuan M, Coyle AJ.

J Immunol. 2016 Jul 1;197(1):42-50. doi: 10.4049/jimmunol.1502190. Epub 2016 May 25.

12.

Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer.

Jiang L, Huang J, Higgs BW, Hu Z, Xiao Z, Yao X, Conley S, Zhong H, Liu Z, Brohawn P, Shen D, Wu S, Ge X, Jiang Y, Zhao Y, Lou Y, Morehouse C, Zhu W, Sebastian Y, Czapiga M, Oganesyan V, Fu H, Niu Y, Zhang W, Streicher K, Tice D, Zhao H, Zhu M, Xu L, Herbst R, Su X, Gu Y, Li S, Huang L, Gu J, Han B, Jallal B, Shen H, Yao Y.

PLoS Genet. 2016 Apr 19;12(4):e1005895. doi: 10.1371/journal.pgen.1005895. eCollection 2016 Apr.

13.

HERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma.

Xue F, Higgs BW, Huang J, Morehouse C, Zhu W, Yao X, Brohawn P, Xiao Z, Sebastian Y, Liu Z, Xia Y, Shen D, Kuziora M, Dong Z, Han H, Gu Y, Gu J, Xia Q, Yao Y.

J Transl Med. 2015 Dec 11;13:379. doi: 10.1186/s12967-015-0743-2.

14.

A high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4+ T cell receptor repertoire clonality.

Zhu W, Germain C, Liu Z, Sebastian Y, Devi P, Knockaert S, Brohawn P, Lehmann K, Damotte D, Validire P, Yao Y, Valge-Archer V, Hammond SA, Dieu-Nosjean MC, Higgs BW.

Oncoimmunology. 2015 Jun 1;4(12):e1051922. eCollection 2015 Dec.

15.

In Vivo Therapeutic Success of MicroRNA-155 Antagomir in a Mouse Model of Lupus Alveolar Hemorrhage.

Zhou S, Wang Y, Meng Y, Xiao C, Liu Z, Brohawn P, Higgs BW, Jallal B, Jia Q, Qu B, Huang X, Tang Y, Yao Y, Harley JB, Shen N.

Arthritis Rheumatol. 2016 Apr;68(4):953-64. doi: 10.1002/art.39485.

16.

Synergistic actions of blocking angiopoietin-2 and tumor necrosis factor-α in suppressing remodeling of blood vessels and lymphatics in airway inflammation.

Le CT, Laidlaw G, Morehouse CA, Naiman B, Brohawn P, Mustelin T, Connor JR, McDonald DM.

Am J Pathol. 2015 Nov;185(11):2949-68. doi: 10.1016/j.ajpath.2015.07.010. Epub 2015 Sep 5.

17.

CD4+ T-Cell Profiles and Peripheral Blood Ex-Vivo Responses to T-Cell Directed Stimulation Delineate COPD Phenotypes.

Roberts MEP, Higgs BW, Brohawn P, Pilataxi F, Guo X, Kuziora M, Bowler RP, White WI.

Chronic Obstr Pulm Dis. 2015 Aug 23;2(4):268-280. doi: 10.15326/jcopdf.2.4.2015.0131.

18.

Neutrophils Regulate Humoral Autoimmunity by Restricting Interferon-γ Production via the Generation of Reactive Oxygen Species.

Huang X, Li J, Dorta-Estremera S, Di Domizio J, Anthony SM, Watowich SS, Popkin D, Liu Z, Brohawn P, Yao Y, Schluns KS, Lanier LL, Cao W.

Cell Rep. 2015 Aug 18;12(7):1120-32. doi: 10.1016/j.celrep.2015.07.021. Epub 2015 Aug 6.

19.

Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression.

Sungalee S, Mamessier E, Morgado E, Grégoire E, Brohawn PZ, Morehouse CA, Jouve N, Monvoisin C, Menard C, Debroas G, Faroudi M, Mechin V, Navarro JM, Drevet C, Eberle FC, Chasson L, Baudimont F, Mancini SJ, Tellier J, Picquenot JM, Kelly R, Vineis P, Ruminy P, Chetaille B, Jaffe ES, Schiff C, Hardwigsen J, Tice DA, Higgs BW, Tarte K, Nadel B, Roulland S.

J Clin Invest. 2014 Dec;124(12):5337-51. doi: 10.1172/JCI72415. Epub 2014 Nov 10.

20.

Inhibition of myogenic microRNAs 1, 133, and 206 by inflammatory cytokines links inflammation and muscle degeneration in adult inflammatory myopathies.

Georgantas RW, Streicher K, Greenberg SA, Greenlees LM, Zhu W, Brohawn PZ, Higgs BW, Czapiga M, Morehouse CA, Amato A, Richman L, Jallal B, Yao Y, Ranade K.

Arthritis Rheumatol. 2014 Apr;66(4):1022-33. doi: 10.1002/art.38292.

21.

Increased IR-A/IR-B ratio in non-small cell lung cancers associates with lower epithelial-mesenchymal transition signature and longer survival in squamous cell lung carcinoma.

Jiang L, Zhu W, Streicher K, Morehouse C, Brohawn P, Ge X, Dong Z, Yin X, Zhu G, Gu Y, Ranade K, Higgs BW, Yao Y, Huang J.

BMC Cancer. 2014 Feb 26;14:131. doi: 10.1186/1471-2407-14-131.

22.

The plasma cell signature in autoimmune disease.

Streicher K, Morehouse CA, Groves CJ, Rajan B, Pilataxi F, Lehmann KP, Brohawn PZ, Higgs BW, McKeever K, Greenberg SA, Fiorentino D, Richman LK, Jallal B, Herbst R, Yao Y, Ranade K.

Arthritis Rheumatol. 2014 Jan;66(1):173-84. doi: 10.1002/art.38194.

23.

MicroRNA-206 induces G1 arrest in melanoma by inhibition of CDK4 and Cyclin D.

Georgantas RW 3rd, Streicher K, Luo X, Greenlees L, Zhu W, Liu Z, Brohawn P, Morehouse C, Higgs BW, Richman L, Jallal B, Yao Y, Ranade K.

Pigment Cell Melanoma Res. 2014 Mar;27(2):275-86. doi: 10.1111/pcmr.12200. Epub 2014 Jan 17.

PMID:
24289491
24.

Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.

Jiang L, Huang J, Morehouse C, Zhu W, Korolevich S, Sui D, Ge X, Lehmann K, Liu Z, Kiefer C, Czapiga M, Su X, Brohawn P, Gu Y, Higgs BW, Yao Y.

Cancer Genet. 2013 Sep-Oct;206(9-10):330-9. doi: 10.1016/j.cancergen.2013.09.004. Epub 2013 Oct 2.

25.

Circulating tumor cells: application as a biomarker for molecular characterization and predictor of survival in an all-comer solid tumor phase I clinical study.

Bao H, Burke PA, Huang J, Chen X, Brohawn PZ, Yao Y, Lechleider RJ, Sikorski RS, Buzoianu M, Zhang J, Shi X, Richman LK, Lavallee TM.

PLoS One. 2013 Aug 21;8(8):e58557. doi: 10.1371/journal.pone.0058557. eCollection 2013.

26.

A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients.

Higgs BW, Zhu W, Morehouse C, White WI, Brohawn P, Guo X, Rebelatto M, Le C, Amato A, Fiorentino D, Greenberg SA, Drappa J, Richman L, Greth W, Jallal B, Yao Y.

Ann Rheum Dis. 2014 Jan;73(1):256-62. doi: 10.1136/annrheumdis-2012-202794. Epub 2013 Feb 23.

27.

The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA.

Peng L, Oberst MD, Huang J, Brohawn P, Morehouse C, Lekstrom K, Baeuerle PA, Wu H, Yao Y, Coats SR, Dall'Acqua W, Damschroder M, Hammond SA.

PLoS One. 2012;7(5):e36412. doi: 10.1371/journal.pone.0036412. Epub 2012 May 4.

28.

Opposing roles of membrane and soluble forms of the receptor for advanced glycation end products in primary respiratory syncytial virus infection.

Miller AL, Sims GP, Brewah YA, Rebelatto MC, Kearley J, Benjamin E, Keller AE, Brohawn P, Herbst R, Coyle AJ, Humbles AA, Kolbeck R.

J Infect Dis. 2012 Apr 15;205(8):1311-20. doi: 10.1093/infdis/jir826. Epub 2012 Jan 18.

29.

Altered expression of insulin receptor isoforms in breast cancer.

Huang J, Morehouse C, Streicher K, Higgs BW, Gao J, Czapiga M, Boutrin A, Zhu W, Brohawn P, Chang Y, Viner J, LaVallee T, Richman L, Jallal B, Yao Y.

PLoS One. 2011;6(10):e26177. doi: 10.1371/journal.pone.0026177. Epub 2011 Oct 26.

30.

Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis.

Greenberg SA, Higgs BW, Morehouse C, Walsh RJ, Kong SW, Brohawn P, Zhu W, Amato A, Salajegheh M, White B, Kiener PA, Jallal B, Yao Y.

Genes Immun. 2012 Apr;13(3):207-13. doi: 10.1038/gene.2011.61. Epub 2011 Sep 1.

PMID:
21881594
31.

A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth.

Streicher KL, Zhu W, Lehmann KP, Georgantas RW, Morehouse CA, Brohawn P, Carrasco RA, Xiao Z, Tice DA, Higgs BW, Richman L, Jallal B, Ranade K, Yao Y.

Oncogene. 2012 Mar 22;31(12):1558-70. doi: 10.1038/onc.2011.345. Epub 2011 Aug 22.

PMID:
21860416
32.

Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway.

Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, Brohawn P, Kiener PA, Richman L, Fiorentino D, Greenberg SA, Jallal B, Yao Y.

Ann Rheum Dis. 2011 Nov;70(11):2029-36. doi: 10.1136/ard.2011.150326. Epub 2011 Jul 28.

PMID:
21803750
33.

Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus.

Yao Y, Richman L, Higgs BW, Morehouse CA, de los Reyes M, Brohawn P, Zhang J, White B, Coyle AJ, Kiener PA, Jallal B.

Arthritis Rheum. 2009 Jun;60(6):1785-96. doi: 10.1002/art.24557.

34.

Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus.

Yao Y, Higgs BW, Morehouse C, de Los Reyes M, Trigona W, Brohawn P, White W, Zhang J, White B, Coyle AJ, Kiener PA, Jallal B.

Hum Genomics Proteomics. 2009 Nov 17;2009. pii: 374312. doi: 10.4061/2009/374312.

Supplemental Content

Loading ...
Support Center